arabinofuranosyluracil has been researched along with Hematologic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blasberg, RG; Doubrovin, M; Doubrovina, E; Finn, R; Gallardo, HF; Koehne, G; Larson, SM; O'Reilly, RJ; Riviere, I; Sadelain, M; Zanzonico, P | 1 |
| Fukushima, T; Gotoh, N; Kishi, S; Masada, M; Matsuyama, S; Nakamura, T; Tsutani, H; Ueda, T; Yamauchi, T | 1 |
1 trial(s) available for arabinofuranosyluracil and Hematologic Neoplasms
| Article | Year |
|---|---|
Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Cytarabine; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Metabolic Clearance Rate; Middle Aged | 1998 |
1 other study(ies) available for arabinofuranosyluracil and Hematologic Neoplasms
| Article | Year |
|---|---|
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.
Topics: Animals; Arabinofuranosyluracil; Cytotoxicity, Immunologic; Dose-Response Relationship, Radiation; Epstein-Barr Virus Infections; Hematologic Neoplasms; Humans; Immunotherapy, Adoptive; In Vitro Techniques; Iodine Radioisotopes; Mice; Mice, SCID; Radionuclide Imaging; Radiopharmaceuticals; T-Lymphocytes; Transduction, Genetic | 2006 |